H.C. Wainwright raised the firm’s price target on BioMarin (BMRN) to $60 from $55 and keeps a Neutral rating on the shares. The firm views the company’s acquisition of Amicus (FOLD as a “strategic move that secures long- term durability of cash flows but places the peak sales payoff firmly in the 2030s.” The payoff to the Amicus deal is “far away,” and until then, Voxzogo remains the focal point of BioMarin shares, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- William Blair views BioMarin acquisition of Amicus as ‘strategic fit’
- Balanced View on BioMarin’s Amicus Acquisition: Strategic Rare-Disease Upside Versus Near-Term Leverage and Earnings Dilution Supports Hold Rating
- BioMarin rises 21.4%
- Midday Fly By: Nike reports Q2 beat, TikTok to sell U.S. unit
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!